Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) Invested Capital (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Invested Capital for 4 consecutive years, with $184.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 5.62% to $184.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $184.7 million, a 5.62% decrease, with the full-year FY2024 number at $161.4 million, down 12.66% from a year prior.
  • Invested Capital was $184.7 million for Q3 2025 at Century Therapeutics, down from $209.9 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $386.7 million in Q1 2022 to a low of $161.4 million in Q4 2024.
  • A 4-year average of $248.1 million and a median of $222.1 million in 2024 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: crashed 40.26% in 2023, then surged 35.17% in 2025.
  • Century Therapeutics' Invested Capital stood at $309.2 million in 2022, then plummeted by 40.26% to $184.8 million in 2023, then decreased by 12.66% to $161.4 million in 2024, then increased by 14.45% to $184.7 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Invested Capital are $184.7 million (Q3 2025), $209.9 million (Q2 2025), and $240.4 million (Q1 2025).